KR890003404A - 수식형 tPA 함유 주사용 조성물 - Google Patents

수식형 tPA 함유 주사용 조성물 Download PDF

Info

Publication number
KR890003404A
KR890003404A KR1019880009479A KR880009479A KR890003404A KR 890003404 A KR890003404 A KR 890003404A KR 1019880009479 A KR1019880009479 A KR 1019880009479A KR 880009479 A KR880009479 A KR 880009479A KR 890003404 A KR890003404 A KR 890003404A
Authority
KR
South Korea
Prior art keywords
amino acid
composition
modified tpa
composition containing
injectable composition
Prior art date
Application number
KR1019880009479A
Other languages
English (en)
Other versions
KR910009366B1 (ko
Inventor
마사히로 가와하라
유우이찌로오 하야시
나오끼 아사까와
스미오 와다나베
야스오 미야께
Original Assignee
나이또오 하루오
에자이 가부시끼가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=16406817&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR890003404(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 나이또오 하루오, 에자이 가부시끼가이샤 filed Critical 나이또오 하루오
Publication of KR890003404A publication Critical patent/KR890003404A/ko
Application granted granted Critical
Publication of KR910009366B1 publication Critical patent/KR910009366B1/ko

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/49—Urokinase; Tissue plasminogen activator
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Detergent Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

내용 없음

Description

수식형 tPA 함유 주사용 조성물
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
제1도는 아미노산의 첨가가 전혀 없이 얻어진 대조품의 결과. 제2도는 L-아르기닌 염산염 3% 첨가의 결과. 제3도는 L-히스티딘 염산염 3% 첨가의 결과.

Claims (7)

  1. 수식형 tPA의 약리학적 유효량, 아미노산 또는 그의염 20mM이상 및 약리학적으로 허용되는 담체로 이루어진 주사용 조성물.
  2. 제1항에 있어서, 아미노산이 염기성 아미노산인 것을 특징으로 하는 조성물.
  3. 제1항에 있어서, 아미노산이 아르기닌, 히스티딘, 리신 및 오르니틴 중에서 채택된 것을 특징으로 하는 조성물.
  4. 제1항에 있어서, 아미노산이 산성 아미노산인 것을 특징으로 하는 조성물.
  5. 제1항에 있어서, 아미노산이 글루탐산 및 아스파라긴산 중에서 채택된 것을 특징으로 하는 조성물.
  6. 제1항에 있어서, 아미노산이 주성 아미노산인 것을 특징으로 하는 조성물.
  7. 제1항에 있어서, 아미노산이 글리신, 알라닌, 발린, 로이신, 세린 및 트레오닌 중에서 채택된 것을 특징으로 하는 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019880009479A 1987-08-10 1988-07-27 수식형 tPA 함유 주사용 조성물 KR910009366B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP62199381A JP2708749B2 (ja) 1987-08-10 1987-08-10 修飾型ｔＰＡ含有注射用組成物
JP62-199381 1987-08-10

Publications (2)

Publication Number Publication Date
KR890003404A true KR890003404A (ko) 1989-04-14
KR910009366B1 KR910009366B1 (ko) 1991-11-14

Family

ID=16406817

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019880009479A KR910009366B1 (ko) 1987-08-10 1988-07-27 수식형 tPA 함유 주사용 조성물

Country Status (11)

Country Link
US (1) US5425943A (ko)
EP (1) EP0303251B1 (ko)
JP (1) JP2708749B2 (ko)
KR (1) KR910009366B1 (ko)
AT (1) ATE84220T1 (ko)
CA (1) CA1338699C (ko)
DE (1) DE3877277T2 (ko)
DK (1) DK443988A (ko)
ES (1) ES2052651T3 (ko)
GR (1) GR3006748T3 (ko)
NO (1) NO178325C (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453363A (en) * 1985-10-23 1995-09-26 Boehringer Mannheim Gmbh Process for the activation of t-PA or Ing after genetic expression in prokaryotes
US4980165A (en) * 1989-01-27 1990-12-25 Genetics Institute, Inc. Pharmaceutical formulations of plasminogen activator proteins
JP2520975B2 (ja) * 1989-09-21 1996-07-31 三井東圧化学株式会社 組織プラスミノ―ゲンアクチベ―タ―若しくはその誘導体を含有する血栓溶解剤
DE3939346A1 (de) * 1989-11-29 1991-06-06 Behringwerke Ag Arzneimitel zur subkutanen oder intramuskulaeren applikation enthaltend polypeptide
US6372716B1 (en) * 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
US5770700A (en) * 1996-01-25 1998-06-23 Genetics Institute, Inc. Liquid factor IX formulations
TWI240627B (en) * 1996-04-26 2005-10-01 Chugai Pharmaceutical Co Ltd Erythropoietin solution preparation
US6139838A (en) * 1996-09-06 2000-10-31 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Tissue plasminogen activator medicinal composition

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS54147916A (en) * 1978-05-12 1979-11-19 Sumitomo Chem Co Ltd Preparation of urokinase injection
EP0125254A1 (en) * 1982-10-28 1984-11-21 Beecham Group Plc Enzyme derivatives and their use in the treatment of thrombosis
GB8334498D0 (en) * 1983-12-24 1984-02-01 Beecham Group Plc Compounds
JPS60181028A (ja) * 1984-02-29 1985-09-14 Asahi Chem Ind Co Ltd 組織プラスミノ−ゲン・アクチベ−タ−の溶解補助法
DE3584902D1 (de) * 1984-02-29 1992-01-30 Asahi Chemical Ind Waessrige loesung eines darin in erhoehter konzentration aufgeloesten gewebe-plasminogen-aktivators und herstellungsverfahren.
JPS60184026A (ja) * 1984-03-01 1985-09-19 Asahi Chem Ind Co Ltd 組織プラスミノ−ゲン・アクチベ−タ−の溶解補助方法
GB8503358D0 (en) * 1985-02-09 1985-03-13 Beecham Group Plc Compounds
GB8508717D0 (en) * 1985-04-03 1985-05-09 Beecham Group Plc Composition
GR861037B (en) * 1985-04-22 1986-07-16 Genentech Inc Novel human tissue plasminogen activator mutants
US4916071A (en) * 1985-08-14 1990-04-10 American Home Products Corporation Poly-kringle plasminogen activator
NZ217331A (en) * 1985-08-26 1989-05-29 Lilly Co Eli Tissue plasminogen activator derivatives and genetically engineered product
US4960702A (en) * 1985-09-06 1990-10-02 Codon Methods for recovery of tissue plasminogen activator
JPH0811066B2 (ja) * 1985-09-30 1996-02-07 インテグレーテッド・ジエネティックス・インコーポレーテッド 組換えｄｎａが生産するヒト子宮プラスミノ−ゲンアクチベ−タ−
JPH0672105B2 (ja) * 1985-10-02 1994-09-14 持田製薬株式会社 血栓溶解剤及びその製法
JPS62120321A (ja) * 1985-11-20 1987-06-01 Eisai Co Ltd ｔＰＡ含有医薬組成物
US4777043A (en) * 1985-12-17 1988-10-11 Genentech, Inc. Stabilized human tissue plasminogen activator compositions
DE3684680D1 (de) * 1985-12-23 1992-05-07 Chiron Corp Peptidplasminogenaktivatoren.
US4935237A (en) * 1988-03-21 1990-06-19 Genentech, Inc. Processes for the preparation of t-PA mutants
US4898826A (en) * 1987-12-10 1990-02-06 Invitron Corporation Method to solubilize tissue plasminogen activator

Also Published As

Publication number Publication date
EP0303251A2 (en) 1989-02-15
NO178325C (no) 1996-03-06
JP2708749B2 (ja) 1998-02-04
DK443988D0 (da) 1988-08-09
EP0303251B1 (en) 1993-01-07
ES2052651T3 (es) 1994-07-16
ATE84220T1 (de) 1993-01-15
KR910009366B1 (ko) 1991-11-14
CA1338699C (en) 1996-11-12
GR3006748T3 (ko) 1993-06-30
EP0303251A3 (en) 1990-01-31
DE3877277D1 (de) 1993-02-18
US5425943A (en) 1995-06-20
JPS6442442A (en) 1989-02-14
NO178325B (no) 1995-11-27
NO883520D0 (no) 1988-08-08
DE3877277T2 (de) 1993-06-03
DK443988A (da) 1989-02-11
NO883520L (no) 1989-02-13

Similar Documents

Publication Publication Date Title
NO911787D0 (no) Peptidaminer samt fremgangsmaate for fremstilling derav.
KR920019371A (ko) 안정화된 인자 ⅷ 제제
DE58906659D1 (de) Stabilisieren von unter Abspaltung von Alkoholen zu Elastomeren vernetzaren Organopolysiloxanmassen.
KR910007958A (ko) 피브리노겐 수용체 길항제
ATE121755T1 (de) Deletionsanaloga von magaininpeptiden.
KR910009246A (ko) 폴리펩타이드를 함유하는 피하투여용 또는 근육내 투여용 약제
DE69723812D1 (de) Aminosäurezusammensetzungen
KR890003404A (ko) 수식형 tPA 함유 주사용 조성물
KR910016767A (ko) 신규한 펩티드
KR840008279A (ko) 아미노산 함유지방유제의 지방미립자화 방법
SE8901552D0 (sv) Acid addition salts of amidated or glycine, their preparation and use
DE3867445D1 (de) Injizierbare loesung des thioctsaeuresalzes mit trometamol und/oder basischen aminosaeuren.
KR950024769A (ko) 고농도 tcf 제제
EP0326490A3 (en) Synthetic peptides and mixtures thereof for detecting hiv antibodies
KR890701571A (ko) 4h-3, 1-벤즈옥사진-4-온 화합물 및 세린 프로테아제 억제를 위한 그의 약학 조성물
SE327779B (ko)
ES2053589T3 (es) Nuevos compuestos de cistina, su fabricacion y empleo.
ATE293598T1 (de) Harnstoffderivate von alpha, omega-diaminosäuren und peptiden
SU527182A1 (ru) Способ получени белковых гидролизатов из водорослей
FI910788A0 (fi) Syntes av lh-rh-analoger medelst temporaer minimal skydd.
KR900003198A (ko) 신규 글루탐산 유도체, 그의 염, 그의 제조방법, 이들의 의약품으로서의 용도 및 이들을 함유한 조성물
GB1058947A (ko)
GB1178149A (en) alpha-(N-Thiocarboxy)-Amino Acid Anhydrides
KR870009713A (ko) 파모티딘의 주사용 조성물의 제조방법
KR880014189A (ko) 발수발유제 조성물

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20011107

Year of fee payment: 11

LAPS Lapse due to unpaid annual fee